Karyopharm Therapeutics Q3 EPS $(3.82) Misses $(3.13) Estimate, Sales $44.000M Beat $41.212M Estimate

Author: Benzinga Newsdesk | November 03, 2025 07:32am
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(3.82) per share which missed the analyst consensus estimate of $(3.13) by 22.04 percent. This is a 2.05 percent increase over losses of $(3.90) per share from the same period last year. The company reported quarterly sales of $44.000 million which beat the analyst consensus estimate of $41.212 million by 6.77 percent. This is a 13.45 percent increase over sales of $38.783 million the same period last year.

Posted In: KPTI